↓ Skip to main content

Dove Medical Press

Article Metrics

Osteoporosis – a current view of pharmacological prevention and treatment

Overview of attention for article published in Drug Design, Development and Therapy, May 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
twitter
4 tweeters
patent
2 patents

Citations

dimensions_citation
188 Dimensions

Readers on

mendeley
193 Mendeley
citeulike
1 CiteULike
Title
Osteoporosis – a current view of pharmacological prevention and treatment
Published in
Drug Design, Development and Therapy, May 2013
DOI 10.2147/dddt.s31504
Pubmed ID
Authors

Julie Crockett, Das

Abstract

Postmenopausal osteoporosis is the most common bone disease, associated with low bone mineral density (BMD) and pathological fractures which lead to significant morbidity. It is defined clinically by a BMD of 2.5 standard deviations or more below the young female adult mean (T-score =-2.5). Osteoporosis was a huge global problem both socially and economically - in the UK alone, in 2011 £6 million per day was spent on treatment and social care of the 230,000 osteoporotic fracture patients - and therefore viable preventative and therapeutic approaches are key to managing this problem within the aging population of today. One of the main issues surrounding the potential of osteoporosis management is diagnosing patients at risk before they develop a fracture. We discuss the current and future possibilities for identifying susceptible patients, from fracture risk assessment to shape modeling and in relation to the high heritability of osteoporosis now that a plethora of genes have been associated with low BMD and osteoporotic fracture. This review highlights the current therapeutics in clinical use (including bisphosphonates, anti-RANKL [receptor activator of NF-κB ligand], intermittent low dose parathyroid hormone, and strontium ranelate) and some of those in development (anti-sclerostin antibodies and cathepsin K inhibitors). By highlighting the intimate relationship between the activities of bone forming (osteoblasts) and bone-resorbing (osteoclasts) cells, we include an overview and comparison of the molecular mechanisms exploited in each therapy.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 193 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
India 2 1%
Portugal 1 <1%
Brazil 1 <1%
Gambia 1 <1%
Spain 1 <1%
United States 1 <1%
Unknown 186 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 30 16%
Student > Master 29 15%
Researcher 23 12%
Student > Bachelor 23 12%
Student > Doctoral Student 15 8%
Other 34 18%
Unknown 39 20%
Readers by discipline Count As %
Medicine and Dentistry 59 31%
Agricultural and Biological Sciences 26 13%
Biochemistry, Genetics and Molecular Biology 25 13%
Pharmacology, Toxicology and Pharmaceutical Science 10 5%
Engineering 5 3%
Other 26 13%
Unknown 42 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 October 2022.
All research outputs
#1,187,042
of 22,509,254 outputs
Outputs from Drug Design, Development and Therapy
#52
of 2,065 outputs
Outputs of similar age
#9,283
of 174,836 outputs
Outputs of similar age from Drug Design, Development and Therapy
#2
of 17 outputs
Altmetric has tracked 22,509,254 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,065 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 174,836 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.